FDA: Gleevec's Latest Approval Is for Pediatric Cancer

FDA: Gleevec's Latest Approval Is for Pediatric Cancer
FDA: Gleevec's Latest Approval Is for Pediatric Cancer

(HealthDay News) -- The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL), the agency said Friday.

Ph+ ALL progresses rapidly if left untreated. Gleevec, among a class of drugs called tyrosine kinase inhibitors, blocks proteins that promote development of cancer cells, the FDA said in a news release.

The most common side effects observed in pediatric testing included infection and a decrease in white blood cells and blood platelets.

Gleevec was first approved in 2001 to treat a form of chronic myeloid leukemia, and has since been approved to treat several other conditions. The drug is marketed by Novartis, based in East Hanover, N.J.

More Information

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs